Pharmacogenetics and psychiatry

被引：6

作者：

Basu A. ^{[1
]}

Tsapakis E. ^{[1
]}

Aitchison K. ^{[1
]}

机构：

[1] Social Genet./Devmtl. Psychiat. Ctr., Institute of Psychiatry, London SE5 8AF, 1 Windsor Walk, Denmark Hill

来源：

Current Psychiatry Reports | 2004年 / 6卷 / 2期

关键词：

Clozapine; Olanzapine; Fluvoxamine; Tardive Dyskinesia; Variable Number Tandem Repeat;

D O I：

10.1007/s11920-004-0053-5

中图分类号：

学科分类号：

摘要：

Genetic factors play a significant role in predicting an individual's response to a drug. The response may be the desired therapeutic effect of the drug and also may be the undesirable development of adverse effects. This relationship between genes and drug response interests the pharmacogeneticist. This article aims to give an overview of the exciting discoveries made so far in the field of psychiatry, particularly concerning the response to antidepressants and antipsychotics, as well as to mention some of the more recent findings. The ultimate goal of pharmacogenetics is to provide medication "tailored" to the individual based on their genetic profile, and although this may currently seem a distant target, it has already begun to raise ethical questions, which also are discussed. Copyright © 2004 by Current Science Inc.

引用

页码：134 / 142

页数：8

共 54 条

[41] Jacobsen F.M., Fluoxetine-induced sexual dysfunction and an open trial of yohimbine, J. Clin. Psychiatry, 53, pp. 119-122, (1992)
[42] Liljedahl U., Karlsson J., Melhus H., Et al., A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response, Pharmacogenetics, 13, pp. 7-17, (2003)
[43] Alfaro C.L., Lam Y.W., Simpson J., Ereshefsky L., CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline, J. Clin. Psychopharmacol., 19, pp. 155-163, (1999)
[44] Murphy G.M., Kremer C., Rodrigues H.E., Schatzberg A.F., Pharmacogenetics of antidepressant medication intolerance, Am. J. Psychiatry, 160, pp. 1830-1835, (2003)
[45] Aitchison K.J., Jordan B., Sharma T.S., The relevance of ethnic influences on pharmacogenetics to the treatment of psychosis, Drug Metab. Drug. Interact, 16, pp. 15-38, (2000)
[46] Duman R.S., Heninger G.R., Nestler E.J., A molecular and cellular theory of depression, Arch. Gen. Psychiatry, 54, pp. 597-606, (1997)
[47] Hashimoto R., Nobuyuki T., Shimazu K., Et al., Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: An essential step for neuroprotection against glutamate excitotoxicity, Neuropharmacology, 43, pp. 1173-1179, (2002)
[48] Fumagalli F., Molteni R., Roceri M., Et al., Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity, J. Neurosci. Res., 72, pp. 622-628, (2003)
[49] Krebs M.O., Guillin O., Bourdell M.C., Et al., Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia, Mol. Psychiatry, 5, pp. 558-562, (2000)
[50] Zill P., Baghai T.C., Zwanzger P., Et al., Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment, Neuroreport, 11, pp. 1893-1897, (2000)

← 1 2 3 4 5 6 →